AI in Drug Development: Use Cases, Data Requirements and Controls

AI in drug development is the use of machine learning, generative models and other AI methods to speed up and improve the steps that take a drug candidate from target selection through preclinical work, clinical trials and manufacturing. It helps teams find better targets and molecules, design smarter studies and spot safety or quality problems earlier, but it only works when the underlying data is clean, traceable and governed.

This guide is for R&D, data and IT leaders at pharma, biotech and life sciences companies who need to decide where AI belongs in their pipeline. It covers the main use cases, the data each one needs, the controls regulators expect once AI output touches a decision, and how to move from a pilot to a validated production system.

What Is AI in Drug Development and Where Does It Fit?

Drug development is a long chain of decisions made on imperfect data: which target to pursue, which compound to advance, which patients to enroll, which dose to test and which batch to release. AI adds value wherever that chain relies on large volumes of data that people cannot review by hand. The usual stages look like this:

• Discovery. Choosing targets, screening compounds, predicting how molecules bind and proposing new structures (this is where most searches for AI for drug discovery land).
• Preclinical. Predicting toxicity and pharmacokinetics, and prioritizing which candidates deserve animal or lab studies.
• Clinical development. Designing protocols, finding sites and patients, monitoring data quality and spotting safety signals.
• Manufacturing and quality. Detecting process drift, predicting equipment failures and supporting batch review.
• Post-market. Triaging adverse event reports and watching real-world data for safety patterns.

The distinction that matters most is between AI used to generate ideas and AI used to produce evidence. A model that proposes a thousand candidate molecules for scientists to test is a research tool. A model whose output supports a claim about safety, effectiveness or quality becomes part of a regulatory decision, and that changes how it must be built, documented and monitored.

Which AI Use Cases in Drug Development Deliver Value Today?

The strongest use cases pair a well-defined question with data the organization already owns. The table below summarizes the most common ones, what they depend on, and where a person must stay in the loop.

Generative AI adds a second layer of uses that are less about molecules and more about documents. Large language models can summarize literature, draft sections of clinical study reports and search internal knowledge bases. Those uses carry their own risks, because a fluent but wrong summary is easy to miss. Grounding answers in approved source documents, as described in this look at retrieval-augmented generation for healthcare, is the standard way to reduce that risk.

What Data Does AI in Drug Development Require?

Most failed AI projects in life sciences fail on data, not on modeling. Research data is scattered across electronic lab notebooks, instrument exports, LIMS, clinical systems and spreadsheets, often with inconsistent identifiers and units. Before any model is trained, a team needs five things:

• Unified, identified records. Compounds, samples, studies, subjects and batches need stable identifiers that match across systems.
• Consistent labels and units. A model trained on assay results recorded with different protocols will learn the differences between protocols instead of the biology.
• Provenance and lineage. For every dataset, the team must be able to say where it came from, what was done to it and which version trained which model.
• Access and privacy controls. Clinical and patient-level data needs de-identification, consent tracking and tight permissions, as covered in how to prepare healthcare data for LLMs without breaking compliance.
• Representative coverage. Training data should reflect the populations, chemistries and conditions where the model will be used. A model built on narrow data will fail quietly outside it.

This is data engineering work before it is data science work. Building pipelines that standardize, version and document research data is the foundation, which is why many programs start with data engineering services rather than a modeling project. Clear ownership and quality rules matter just as much, and the relationship between those rules and AI oversight is explained in this article on where data governance and AI governance meet.

What Controls Do Regulators Expect When AI Supports a Decision?

Regulators have started to describe how they expect AI to be handled once it influences evidence. The U.S. Food and Drug Administration published a draft guidance in January 2025, Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products (opens in new tab). It applies to AI models used to produce information or data that supports regulatory decisions about the safety, effectiveness or quality of drugs. It does not address AI used in drug discovery, or AI used for operational efficiencies such as internal workflows, resource allocation or drafting a regulatory submission, when those uses do not affect patient safety, drug quality or the reliability of study results.

The guidance proposes a risk-based credibility assessment framework built around a specific context of use, which is the precise role the model plays in answering a question. It has seven steps:

• Define the question of interest the model will help answer.
• Define the context of use for the model.
• Assess the model risk, which combines model influence (how much the output drives the decision) and decision consequence (how serious an incorrect decision would be).
• Develop a plan to establish the credibility of the model output within that context of use.
• Execute the plan.
• Document the results and discuss any deviations from the plan.
• Determine whether the model is adequate for the context of use.

The European Medicines Agency has taken a similar direction. Its reflection paper on the use of artificial intelligence in the lifecycle of medicines (opens in new tab), adopted by the EMA's human and veterinary medicines committees (CHMP and CVMP) in September 2024, sets out principles for applying AI and machine learning at any step of a medicine's lifecycle, from drug discovery to the post-authorisation setting.

Both documents point to the same practical idea: the more a model influences a high-stakes decision, the more evidence you need that it can be trusted for that exact purpose. Teams translate that into controls they can build and audit:

Early engagement with the regulator is part of the picture. The FDA draft encourages sponsors to engage with the agency early when they are uncertain whether their use of AI is within scope, or how to plan credibility activities.

How Do You Move From an AI Pilot to a Validated System?

Pilots in drug development often succeed in a notebook and stall when someone asks how the model will run, be monitored and be audited. A path that avoids this has five stages:

• Pick one decision, not one technology. Start from a decision the team already makes and can measure, such as which compounds to advance or which sites to activate.
• Classify the use. Decide early whether the output is a research aid or supports evidence for a regulatory decision, and write the context of use accordingly.
• Fix the data foundation. Standardize identifiers, units and lineage for the datasets the model needs before training begins.
• Build for production from the start. Use versioned pipelines, reproducible training, automated tests and monitoring, the practices covered in MLOps.
• Run it under governance. Assign owners, approval steps and review cycles, so each model has a named accountable person and a documented life cycle. AI governance is easier to set up before the first model ships than after the fifth.

Security and privacy need the same early attention. Patient-level and trial data should stay inside a controlled boundary, a design pattern described in healthcare AI that keeps PHI inside the boundary. For teams without in-house capacity to build and validate these systems, AI implementation services cover strategy, engineering and deployment under one roof, and Sphere's healthcare practice works with providers and life sciences teams on exactly these data and compliance questions.

What Are the Biggest Risks of AI in Drug Development?

The risks are well understood, and each has a practical mitigation:

• Bias and narrow training data. Models trained on limited populations or chemistries can fail on new ones. Mitigate with representative data and subgroup testing.
• Unexplainable outputs. If scientists cannot see why a model ranked a candidate highly, they cannot challenge it. Prefer methods and tooling that expose the factors behind a result.
• Data leakage. Information from test sets can slip into training and inflate results. Use strict splits and independent evaluation.
• Model drift. Assay methods, patient populations and manufacturing conditions change. Monitor performance and define revalidation triggers.
• Over-reliance. A confident-sounding output can be accepted without scrutiny. Keep human review on every decision that carries consequences.

None of these is a reason to avoid AI. They are the reason to treat each model as a regulated asset with an owner, a scope and a life cycle, rather than as a one-off experiment.

Frequently Asked Questions About AI in Drug Development